Navigation Links
Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer
Date:1/14/2014

onia. Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a longer-acting PEGylated rFVIII program, which is completing Phase 3 clinical development.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. 

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Cautionary Note Regarding Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "could," "potential," "may" and similar references to future periods. Examples of forward-looking statements include our current views regarding the potential of etirinotecan pegol as a potential new therapy for patients with metastatic breast cancer that have failed other available therapies; the estimated timeline for the availability of top-line data from the BEACON clinical study and, if the study is successful, the timing of regulatory filings with health authorities; the value of our polymer conjugate technology platform; and the potential of certain of our other drug candidates and those of our collaboration partners. Forward-looking statements are neither historical facts nor assuranc
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
2. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
3. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
4. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
5. CAS REGISTRY(SM) surpasses 75 million small molecules
6. WuXi Manufacturing Facility Passes FDA Inspection
7. Tecfideras Patient Share at Three Months Postlaunch Surpasses That for Aubagio and Gilenya At the Same Stage of Their Launches
8. Emotivs Brainwear Technology To Track Cognitive Health Surpasses $1M Kickstarter Stretch Goal
9. The Leukemia & Lymphoma Society Co-Pay Assistance Fund Surpasses $200 Million
10. French Man with SynCardia Total Artificial Heart Surpasses Two Years of Support
11. NABPs .PHARMACY Proposal Passes Initial ICANN Evaluation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... -- DigiPath, Inc. (OTCBB and OTCQB: DIGP), a digital pathology ... and education markets, announced today that has been no ... disclosed or, to its knowledge, any other reason to ... "We have noticed unusual price and volume increases for ... Steve Barbee , CEO of DigiPath. "While we ...
(Date:7/30/2014)... and NEW YORK , ... ACCP), a developer of new products for oncology supportive ... MuGard ® , has been featured in an article ... Mucositis Symptoms in Head and Neck Cancers."  Dr. ... provides insight on the growing demand seen in the ...
(Date:7/30/2014)... -- Hospira, Inc. (NYSE: HSP ), the ... technologies, today reported results for the second quarter ... quarter were $1.1 billion and adjusted* diluted earnings ... items as described later in this press release ... Accepted Accounting Principles (GAAP) basis, second-quarter 2014 diluted ...
Breaking Medicine Technology:DigiPath No New Corporate Developments 2Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30Hospira Reports Second-Quarter 2014 Results 31
... 26, 2012 Interventional Spine, Inc. today announced ... Body Fusion Device. (Logo: ... Access Instrument, which provides unparalleled percutaneous access to ... an integral part of Interventional Spine,s revolutionary PerX360 ...
... VIEW, Calif., Jan. 25, 2012  IRIDEX Corporation (Nasdaq: ... clinical study evaluating the use of IRIDEX, MicroPulse ... effectiveness with patients diagnosed with central serous chorioretinopathy ... is superior to anti-VEGF injections for CSC, also ...
Cached Medicine Technology:Interventional Spine, Inc. Announces FDA Clearance of its Opticage™ Expandable Interbody for Treatment of Degenerative Disc Disease 2IRIDEX MicroPulse™ Laser Therapy Enhances Visual Function in Patients with Central Serous Chorioretinopathy (CSC) 2IRIDEX MicroPulse™ Laser Therapy Enhances Visual Function in Patients with Central Serous Chorioretinopathy (CSC) 3
(Date:7/30/2014)... Serial entrepreneur, Paul Mata, spent the early ... like most people, in 2008 he suffered extreme financial hardship ... way, Paul carefully studied the difference between people who have ... Based on the knowledge he acquired, he was able to ... and health, but also grow his clients' personal and financial ...
(Date:7/30/2014)... 30, 2014 Ticket Down is a ... in Ann Arbor, MI on Saturday, August 2nd. Two ... football will be competing on American soil on Aug. 2 when ... Ann Arbor, Mich. The home of the University of Michigan is ... most prestigious in all of American sports and has also hosted ...
(Date:7/30/2014)... Alan Mozes HealthDay Reporter ... to help their preschooler shed excess pounds may want to ... whose parents joined them in a supervised behavioral modification program ... a traditional child-only program (an average difference of about four ... almost 15 pounds over two years, according to the study. ...
(Date:7/30/2014)... as evolutionary changes in a living organismhad been thought ... genome. , However, recent studies have shown that cancer ... arise simultaneously and in close proximity to each other. ... regions where chromosomal rearrangements take place. , The discovery, ... one day lead to new cancer therapies, according to ...
(Date:7/30/2014)... July 30, 2014 Hamilton Facial ... of its new Carmel office on July 30th. After ... finally be moving to the state-of-the-art suite, located only ... innovative space will allow for one-on-one patient comfort, shorter ... experience. , Dr. Hamilton’s new office-suite will continue ...
Breaking Medicine News(10 mins):Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 3Health News:Manchester United vs. Real Madrid Tickets Ann Arbor: Ticket Down Slashes Ticket Prices for Real Madrid vs. ManU Guinness International Champions Cup Match 2Health News:Manchester United vs. Real Madrid Tickets Ann Arbor: Ticket Down Slashes Ticket Prices for Real Madrid vs. ManU Guinness International Champions Cup Match 3Health News:Manchester United vs. Real Madrid Tickets Ann Arbor: Ticket Down Slashes Ticket Prices for Real Madrid vs. ManU Guinness International Champions Cup Match 4Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 2Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 3Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 4Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2
... , INDIANAPOLIS , Feb. 16 WellPoint, Inc. ... for February 23, 2010 , and announced that management will review ... 17, 2010 , at 8:30 a.m. Eastern Daylight Time (EDT). ... at least $6.00 per share, subject to its ability to ...
... ... enhance health care and medical education in more than 40 countries. With two new medical ... East. , ... 16, 2010 -- Partners Harvard Medical International (PHMI) has signed agreements with two ...
... , ... Silicones is,launching a new line of TCS 7560 and TCS ... and medical applications (support,stockings and medical equipment). These two new ... (Photo: http://www.newscom.com/cgi-bin/prnh/20100216/377913 ) , ...
... Toxic ... , ... February 16, 2010 -- Residents of a luxury Manhattan apartment building are rightfully concerned ... shows that dust in their apartments has higher levels of a carcinogen than what was ...
... ... for the Rosemere Cancer Foundation by cycling coast to coast. , ... (PRWEB) February 16, 2010 -- Last week 13 brave ... raised on a 136 mile/ 3 day charity bike ride last year in memory of ...
... ... a premier leader of the Translation, Transcription and Interpretation industries just completed its initial ... for the booming industry growth expected in the coming year. The quarter century-old ... , ...
Cached Medicine News:Health News:WellPoint To Hold Conference Call and Webcast To Discuss 2010 Financial Outlook on March 17, 2010 2Health News:WellPoint To Hold Conference Call and Webcast To Discuss 2010 Financial Outlook on March 17, 2010 3Health News:WellPoint To Hold Conference Call and Webcast To Discuss 2010 Financial Outlook on March 17, 2010 4Health News:WellPoint To Hold Conference Call and Webcast To Discuss 2010 Financial Outlook on March 17, 2010 5Health News:Partners Harvard Medical International Set to Play Key Role as Saudi Arabia Pursues Ambitious Health Care Transformation 2Health News:Bluestar Silicones Launches a New Range of Silbione(R) TCS 7560 & 7561 Elastomers for Lingerie, Support Stockings and Medical Textile Applications 2Health News:Toxic Construction Dust in Luxury New York Apartments Endangers Health, Angers Accident Attorneys Like David Perecman 2Health News:Plumbs Pedal Power Raises Over 6000 for Charity 2Health News:Language Service Leader Expands to Meet Booming, Global Industry Demand. 2Health News:Language Service Leader Expands to Meet Booming, Global Industry Demand. 3Health News:Language Service Leader Expands to Meet Booming, Global Industry Demand. 4Health News:Language Service Leader Expands to Meet Booming, Global Industry Demand. 5
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: